Supernus Pharmaceuticals (NASDAQ:SUPN) Director Georges Gemayel Sells 10,000 Shares

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Georges Gemayel sold 10,000 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $53.71, for a total value of $537,100.00. Following the transaction, the director directly owned 28,159 shares in the company, valued at $1,512,419.89. This represents a 26.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Georges Gemayel also recently made the following trade(s):

• On Friday, March 6th, Georges Gemayel sold 8,787 shares of Supernus Pharmaceuticals stock. The stock was sold at an average price of $53.00, for a total transaction of $465,711.00.

Supernus Pharmaceuticals Stock Up 0.6%

NASDAQ:SUPN opened at $54.17 on Tuesday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $59.68. The firm’s fifty day simple moving average is $51.05 and its 200-day simple moving average is $48.90. The stock has a market cap of $3.12 billion, a PE ratio of -79.66, a price-to-earnings-growth ratio of 1.67 and a beta of 0.70.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LLC purchased a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth about $237,000. Sit Investment Associates Inc. grew its stake in Supernus Pharmaceuticals by 0.4% in the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock worth $3,240,000 after acquiring an additional 250 shares during the period. Invesco Ltd. raised its holdings in Supernus Pharmaceuticals by 9.4% in the 4th quarter. Invesco Ltd. now owns 395,761 shares of the specialty pharmaceutical company’s stock valued at $19,669,000 after acquiring an additional 33,895 shares during the last quarter. Mackenzie Financial Corp acquired a new position in Supernus Pharmaceuticals in the 4th quarter valued at $223,000. Finally, Zacks Investment Management purchased a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth $1,807,000.

Analyst Upgrades and Downgrades

SUPN has been the topic of a number of research reports. Stifel Nicolaus upped their price target on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a report on Friday, December 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Finally, Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $62.17.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.